Finance

Lists
Why is PALI up 6.55%?
Dive Deeper
PALI:NASDAQ
Palisade Bio Inc
$1.54
+6.55%
(+0.095) 1D
Oct 9, 1:27:24 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PALI...
Open
$1.49
High
$1.57
Low
$1.47
Mkt. cap
269.25M
Avg. vol.
3.16M
Volume
932.16K
52-wk high
$2.86
52-wk low
$1.32
EPS
-$0.64
Beta
1.61
Shares outstanding
174.27M
No. of employees
14
Open
$1.49
High
$1.57
Low
$1.47
Mkt. cap
269.25M
Avg. vol.
3.16M
Volume
932.16K
52-wk high
$2.86
52-wk low
$1.32
EPS
-$0.64
Beta
1.61
Shares outstanding
174.27M
No. of employees
14
News stories
From web sources and news partners
About Palisade Bio Inc
CEO-
Employees14
Founded2005
HeadquartersCarlsbad, California, United States
SectorBiotechnology
Websitepalisadebio.com
Analyst ratings
Based on 6 analysts giving stock ratings to PALI in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PALI in the last 3 months.
Highest
Current $1.54
$25.00 (+1,518.12%)
Average
$10.17 (+558.25%)
Lowest
$6.00 (+288.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Raymond James
Buy
Initiated
$6.00
+288.3%
10/08/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$25.00
+1,518.1%
09/23/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$7.00
+353.1%
09/23/2026
Naz Rahman
Maxim Group
Buy
Reiterated
$8.00
+417.8%
08/12/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$7.00
+353.1%
08/12/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$8.00
+417.8%
08/11/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$5.00
+223.6%
07/06/2026
William Wood
B. Riley Securities
Buy
Reiterated
$7.00
+353.1%
06/02/2026
Andy Chen
Wolfe Research
Buy
Initiated
$7.00
+353.1%
04/08/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$12.00
+676.7%
03/31/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
500.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.39M
6.17M
6.40M
7.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.53M
3.81M
4.35M
4.80M
Operating expense
2.92M
9.98M
10.75M
12.20M
Total operating expenses
2.92M
9.98M
10.75M
12.20M
Operating income
-2.92M
-9.98M
-10.75M
-11.70M
Other non operating income
59.00K
1.08M
1.15M
1.12M
EBT including unusual items
-2.87M
-8.90M
-9.60M
-10.57M
EBT excluding unusual items
-2.87M
-8.90M
-9.60M
-10.57M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.87M
-8.90M
-9.60M
-10.57M
Net profit margin
-
-
-
-2,114.80%
Earnings per share
-0.38
-
-0.05
-0.05
Interest and investment income
-
-
-
-
Interest expense
-5.00K
-2.00K
-1.00K
-
Net interest expenses
-5.00K
-2.00K
-1.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.92M
-9.98M
-10.75M
-11.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps